Current Applications of Artificial Intelligence to Classify Cervical Lymph Nodes in Patients with Head and Neck Squamous Cell Carcinoma-A Systematic Review.
Matthias SanterMarcel KloppenburgTimo Maria GottfriedAnnette RungeJoachim SchmutzhardSamuel Moritz VorbachJulian MangesiusDavid RiedlStephanie MangesiusGerlig WidmannHerbert RiechelmannDaniel DejacoWolfgang FreysingerPublished in: Cancers (2022)
Locally-advanced head and neck squamous cell carcinoma (HNSCC) is mainly defined by the presence of pathologic cervical lymph nodes (LNs) with or without extracapsular spread (ECS). Current radiologic criteria to classify LNs as non-pathologic, pathologic, or pathologic with ECS are primarily shape-based. However, significantly more quantitative information is contained within imaging modalities. This quantitative information could be exploited for classification of LNs in patients with locally-advanced HNSCC by means of artificial intelligence (AI). Currently, various reviews exploring the role of AI in HNSCC are available. However, reviews specifically addressing the current role of AI to classify LN in HNSCC-patients are sparse. The present work systematically reviews original articles that specifically explore the role of AI to classify LNs in locally-advanced HNSCC applying Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines and the Study Quality Assessment Tool of National Institute of Health (NIH). Between 2001 and 2022, out of 69 studies a total of 13 retrospective, mainly monocentric, studies were identified. The majority of the studies included patients with oropharyngeal and oral cavity (9 and 7 of 13 studies, respectively) HNSCC. Histopathologic findings were defined as reference in 9 of 13 studies. Machine learning was applied in 13 studies, 9 of them applying deep learning. The mean number of included patients was 75 (SD ± 72; range 10-258) and of LNs was 340 (SD ± 268; range 21-791). The mean diagnostic accuracy for the training sets was 86% (SD ± 14%; range: 43-99%) and for testing sets 86% (SD ± 5%; range 76-92%). Consequently, all of the identified studies concluded AI to be a potentially promising diagnostic support tool for LN-classification in HNSCC. However, adequately powered, prospective, and randomized control trials are urgently required to further assess AI's role in LN-classification in locally-advanced HNSCC.
Keyphrases
- artificial intelligence
- machine learning
- deep learning
- locally advanced
- neoadjuvant chemotherapy
- big data
- rectal cancer
- lymph node
- squamous cell carcinoma
- case control
- radiation therapy
- phase ii study
- end stage renal disease
- newly diagnosed
- high resolution
- ejection fraction
- convolutional neural network
- public health
- healthcare
- randomized controlled trial
- risk assessment
- open label
- prognostic factors
- mental health
- systematic review
- cross sectional
- health information
- photodynamic therapy
- social media
- patient reported outcomes
- clinical trial
- patient reported
- phase iii